Combination non-targeted and sGRP78-targeted nanoparticle drug delivery outperforms either component to treat metastatic ovarian cancer

Q: How does OCRA curate its research paper database?

OCRA indexes peer-reviewed papers from PubMed and CrossRef, enriched with MeSH terms, author profiles, and citation metrics. Papers are categorized by cancer type, research method, and clinical relevance.

Q: Can I search papers by MeSH term or author?

Yes. Use the search bar to filter papers by MeSH term, author name, journal, keyword, or cancer type. Each paper includes linked MeSH terms and author profiles for further exploration.

Q: How current is the paper database?

The database is updated regularly through automated ingestion from PubMed and CrossRef. Most papers appear within days of their PubMed indexing date.

doi:10.1016/j.jconrel.2024.09.014

Combination non-targeted and sGRP78-targeted nanoparticle drug delivery outperforms either component to treat metastatic ovarian cancer

Jenna N. Sjoerdsma & Basar Bilgicer et al. · 2024-09-19

Metastatic ovarian cancer (MOC) is highly deadly, due in part to the limited efficacy of standard-of-care chemotherapies to metastatic tumors and non-adherent cancer cells. Here, we demonstrated the effectiveness of a combination therapy of GRP78-targeted (TNP

Links

DOI PubMed

Journal

Journal of Controlled Release

Authors

Jenna N. Sjoerdsma, Emily K. Bromley, Jaeho Shin, Tyvette Hilliard, Yueying Liu, Caitlin Horgan, Gyoyeon Hwang, Michael Bektas, David Omstead, Tanyel Kiziltepe, M. Sharon Stack, Basar Bilgicer

Funding

Receptor Cross-Talk in Early Metastatic Dissemination Aging and the Ovarian Tumor Microenvironment University of Notre Dame Mike and Josie Harper Cancer Research Institute Funding National Institutes of Health Funding National Cancer Institute Grant RO1CA109545 National Cancer Institute Grant UO1CA236979

NCI NIH HHS

R01 CA109545

NCI NIH HHS

U01 CA236979